Introduction:
Pluri, a cell therapy company, is expanding its capabilities into the contract development and manufacturing organization (CDMO) space. This move will allow Pluri to offer end-to-end solutions for cell therapy development, including process development, manufacturing, and regulatory support.
- Pluri has expanded its facilities with a new manufacturing site in the United States, which will house its CDMO operations.
- The company aims to address the growing demand for cell and gene therapies by providing a comprehensive suite of services to support the development and manufacturing of these therapies.
- Pluri’s CDMO services will include process development, technology transfer, cGMP manufacturing, fill-finish, quality control, and analytical support.
- The company will also provide regulatory and clinical support, ensuring compliance with regulatory requirements and facilitating the transition from the preclinical to the clinical stage of development.
- By offering end-to-end solutions, Pluri aims to streamline the development and manufacturing process for cell and gene therapies, accelerating their delivery to patients.
Conclusion:
Pluri’s expansion into the CDMO space allows the company to provide a comprehensive range of services for cell and gene therapy development and manufacturing. This move not only addresses the increasing demand for these therapies but also streamlines the development process, ultimately benefiting patients in need of innovative treatments. With its new manufacturing site and expertise in cell therapy, Pluri is well-positioned to support the biotechnology industry in advancing these groundbreaking therapies.
